## **MEDI 306**

# Sulfonyl-polyol N,N-dichloroamines with fast-acting, broad-spectrum antimicrobial activity

## Abstract

*N*,*N*-Dichloroamines with polyol solubilizers have fast-acting, bactericidal and virucidal activity and are suitable for the topical treatment of infectious diseases of the skin. These agents show excellent activity against a broad range of bacterial and viral pathogens, both at pH 4 and pH 7. The sulfonyl-polyol series showed 1-hour MBC's of 16-512 ug/mL against E. coli and 4-512 ug/mL against S. aureus at neutral pH, and 1hour  $IC_{50}$ 's of 4.8 and 0.7-58 uM against HSV-1. The tissue culture irritancy assay and lead compounds shows only mini ghest concentrations tested.

Cl <sub>2</sub> N S X O OH n
<b>1a-m</b> : X = (CH <sub>2</sub> ) <sub>m</sub> <b>2a-b</b> : X = NMe

MBC (*E.coli*) 16-512 ug/ml MBC (S. aureus) 4-512 ug/ml C<sub>50</sub> (Ad5) 4.5-80 uM

## Introduction


Bacteria and viruses are quickly developing resistance to currently marketed drugs. To address this problem, an antimicrobial agent with rapid bactericidal and virucidal activity and low potential for resistance development is desired. N,N-Dichlorotaurine analogs are based on the naturally occurring N-chlorotaurine, which is produced by the body's neutrophils to kill microbial pathogens. The analogs reported within this poster are potential candidates for the treatment of topical infections with mixed viral/bacterial pathogenesis such as epidemic keratoconjunctivitis (EKC).

Table 2: Compounds 1f-i



## Synthesis of Polyols by Alkylation

Intermediate **3** was synthesized as previously reported. Alkylation of the sulfide with a haloalkanol or epoxide furnished alcohols 4a-e, which on oxidation with mCPBA afforded sulfone-alcohols 5a-e. The sulfonealcohols were *N*-deprotected by hydrogenation and chlorinated with *tert*butylhypochlorite to give compounds **1a-e**. The enantiomers of **1e** were synthesized and tested separately from enantiomerically pure glycidol.



Conditions: (a) alkylating agent, Cs<sub>2</sub>CO<sub>3</sub>, DMF; (b) mCPBA, DCM, 0 °C; (c) H<sub>2</sub> (1.3 atm), 10% Pd/C, MeOH; then t-BuOCI, MeOH, 0 °C.

Alkylating Agent	X	n	Entry
$I-(CH_2)_2OH$	CH <sub>2</sub>	1	1a
Br-(CH <sub>2</sub> )-3OH	$(CH_2)_2$	1	1b
CI-CH <sub>2</sub> C(CH <sub>3</sub> ) <sub>2</sub> CH <sub>2</sub> OH	$CH_2C(CH_3)_2$	1	1c
Br-(CH <sub>2</sub> ) <sub>8</sub> OH	(CH <sub>2</sub> ) <sub>7</sub>	1	1d
(±)-glycidol	CH <sub>2</sub>	2	1e
(R)-glycidol	CH <sub>2</sub>	2	R-1e
(S)-glycidol	CH <sub>2</sub>	2	S-1e

Table 1: Compounds 1a-e


5-80 uM Is were imal irrita	tested	in a	a t
2N		ОН	N N 10

IC<sub>50</sub> (HSV-1) 0.7-58 uM

NovaBay Pharmaceuticals, 5980 Horton Street, Suite 550, Emeryville, CA 94608 ACS National Meeting August 28-September 1, 2011 (Denver, CO)

## Synthesis of Polyols by Dihydroxylation

Intermediate 3 was also alkylated with alkenes which were in turn dihydroxylated to the corresponding diols. Treatment of **3** with butadiene monoepoxide provided a 2:1 mixture of 6f (1° attack of epoxide) and 6g (2° attack of epoxide), which were separable by silica gel chromatography. Alkylation of **3** by butene and hexene derivatives to give 6h and 6i was straightforward. Oxidation of both the alkene and the sulfide was accomplished with catalytic OsO<sub>4</sub> and 3 equivalents of NMO; sulfone-polyols 7f-i were isolated, 7f and 7g as 4:1 and 2:1 mixtures of diastereomers which were not separated. Deprotection and Nchlorination afforded compounds 1f-i.




Conditions: (a) alkylating agent, Cs<sub>2</sub>CO<sub>3</sub>, DMF; (b) OsO<sub>4</sub> (cat.), NMO, acetone; (c) H<sub>2</sub> (1.3 atm), 10% Pd/C, MeOH; then t-BuOCI, MeOH, 0 °C.

Alkylating Agent	X	Entry
butediene menenenside	CH <sub>2</sub> CH(OH)	1f
butadiene monoepoxide	CH(CH <sub>2</sub> OH)	1g
$Br-(CH_2)_2CH=CH_2$	(CH <sub>2</sub> ) <sub>2</sub>	1h
$Br-(CH_2)_4CH=CH_2$	(CH <sub>2</sub> ) <sub>4</sub>	<b>1i</b>

## Saccharide-linked Dichloroamine

Intermediate 3 can be alkylated with a wide range of alcohols. Alkylation with a protected monosaccharide afforded compound 8, which was oxidized to **9**, and deprotected/chlorinated to give **1j**.




Conditions: (a) 6-bromo-1-methoxy-a-glucopyranose,  $Cs_2CO_3$ , DMF; (b) mCPBA, DCM, 0 °C; (c) H<sub>2</sub> (1.3 atm), 10% Pd/C, MeOH; then *t*-BuOCI, MeOH, 0 °C. Conditions: (a) HOCI,  $H_2O$ ; (b) MeHN(CH--<sub>2</sub>)<sub>n</sub>OH; (c)  $H_2$  (1.3 atm), 10% Pd/C, MeOH; then *t*-BuOCI, MeOH, 0 °C.


• All compounds showed strong bactericidal (S. aureus and E. coli) and virucidal (adenovirus serotype 5) activity at pH 4, with only minor (2-fold) changes in activity across the series. Compound 1j displayed decreased activity; however, this may only be a function of the lower molar concentration due to its higher molecular weight.

• Compounds 1a and 1e showed minimal pH dependence and were also very active against both bacteria and viruses at pH 7.


• Compounds 1a and 1c show high nanomolar potency against HSV-1. All compounds tested in this series against HSV-1, a lipid-enveloped virus, showed extremely potent activity. It may be plausible that electrically-neutral molecules allows permation into lipid bilayers; however, more study is warranted.

These sulfone-extended, polyol-solubilized dichloroamines have potent virucidal and bactericidal activity. Compounds 1a and 1e have been selected for *in vivo* studies against viral conjunctivitis.





Conditions: (a) 1.2 eq. or 2.5 eq.  $Ac_2O$ , pyridine, DMAP, DCM, 0 °C; (b)  $H_2$  (1.3 atm), 10% Pd/C, MeOH; then *t*-BuOCI, MeOH, 0 °C.



Conditions: (a) ICH<sub>2</sub>CH<sub>2</sub>OH, Cs<sub>2</sub>CO<sub>3</sub>, DMF; (b) mCPBA, DCM, 0 °C; (c) H<sub>2</sub> (1.3 atm), 10% Pd/C, MeOH; then t-BuOCI, MeOH, 0 °C.

Two sulfonamide-linked analogs were synthesized as well. Intermediate **13** was oxidized with aqueous HOCI to afford sulfonyl chloride **14**, which was then reacted with *N*-methylaminoalcohols to give sulfonamides **15ab**. The sulfonamides were then *N*-deprotected and *N*-chlorinated to give compounds 2a-b.


## Timothy P. Shiau, Eddy Low, Bum Kim, Eric D. Turtle, Charles Francavilla, Donogh J. R. O'Mahony, Lisa Friedman, Louisa D'Lima, Andreas Jekle, Meghan Zuck, Nichole J. Alvarez, Mark Anderson, Ramin (Ron) Najafi and Rakesh K. Jain

## **Acylated Polyols**


Two acetylated derivatives of 1e were synthesized by acetylation of intermediate 5e. Treatment with 1 eq. acetic anhydride afforded monoacetyl derivative **10k** which was deprotected and *N*-chlorinated to give 1k, while an excess of acetic anhydride afforded diacetyl derivative **10I** which was deprotected and *N*-chlorinated to give **1I**.

## Shortened Linker

In previous studies we have shown that a spacer of two methylenes between a sulfone and dichloroamine was ideal for chemical stability; we synthesized the one-methylene analog of **1a** to confirm this hypothesis. intermediate reported was alkylated, oxidized, deprotected, and N-chlorinated in a sequence similar to that for **1a** to afford **1m**.



## Sulfonamide Linker




## **Results and Conclusions**

Prior to antimicrobial testing, all compounds were screened for stability. In several cases, compounds were unstable in aqueous solution and were not tested for *in vitro* antimicrobial activity. In one case (2b), the compound was stable in aqueous solution but unstable as a solid.

	pH 4			pH 7			
	MBC <i>E. coli</i>	MBC S. aureus	IC <sub>50</sub> Ad5	MBC <i>E. coli</i>	MBC S. aureus	IC <sub>50</sub> Ad5	IC <sub>50</sub> HSV
Entry	(ug/ml)	(ug/ml)	(uM)	(ug/ml)	(ug/ml)	(uM)	(uM)
<mark>1</mark> а	0.5	1	1.4	8	16	4.5	0.7
1b	*	*	*	*	*	*	*
1c	4	2	1.8	64	128	9.6	0.9
1d	*	*	*	256	1	nt	nt
<b>1e</b>	2	2	2.7	16	4	25.5	1.5
R-1e	2	2	2.2	32	4	14.1	1.0
S-1e	2	1	2.4	32	4	13.6	1.2
1f	2	1	nt	128	32	nt	nt
1g	2	2	1.5	64	16	18.6	3
1h	2	1	1.4	64	16	18.1	1.2
<b>1</b> i	*	*	*	*	*	*	*
1j	8	8	nt	512	256	nt	nt
1k	2	4	nt	64	32	nt	nt
11	1	2	nt	128	128	nt	nt
1m	1	1	2.2	*	*	*	*
2a	2	1	1.5	64	128	14.0	1.2
2b	*	*	*	*	*	*	*

nt = not tested based on MBC values. \* = not tested due to compound stability

EpiOcular tis
and 100 µl te
varying expo
an MTT solut
viability was
correlated w
Mattek's instr





### Timothy Shiau Phone (510)-899 8862 tshiau@novabaypharma.com

## **Biological Activity**

### Irritancy

ssues (Mattek Corp.) were placed in 900 µl cell culture media est compound was added to the apical side of the tissue for osure times. Tissues were rinsed with 1x PBS and placed in tion for 3 hours. Tissues were extracted overnight and tissue determined by MTT absorbance. Tissue viability was ith a Draize-type score for tissue irritancy according to ructions.